Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical leader pioneering targeted immuno-oncology therapies through its proprietary ROCK® platform. This page serves as the definitive source for Affimed news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Key resources include: Press releases on clinical trial progress, regulatory milestones, and strategic partnerships; financial reports detailing earnings and R&D investments; and analyses of bispecific antibody innovations. Users gain streamlined access to Affimed's latest innate cell engager (ICE®) research and pipeline updates across hematologic and solid tumors.
Content highlights: Clinical trial results, FDA/EMA regulatory filings, collaboration announcements with biopharma partners, and presentations at major medical conferences. Bookmark this page to efficiently track Affimed's progress in advancing next-generation cancer immunotherapies.
Affimed (NASDAQ: AFMD) announced positive results from the LuminICE-203 phase 2 study, evaluating the combination of acimtamig with AlloNK® in relapsed/refractory classical Hodgkin Lymphoma patients. The trial included 22 heavily pretreated patients who had received a median of 5 prior therapies.
The combination demonstrated an overall response rate of 86% and a complete response rate of 55%. The treatment showed a well-manageable safety profile with no unexpected safety signals, and notably, no cases of graft-versus-host disease or immune effector cell-associated neurotoxicity syndrome were reported.
All patients had previously received intensive combination chemotherapy, PD(L)1 checkpoint inhibitors, and brentuximab vedotin, with approximately two-thirds having undergone stem cell transplant.
Affimed (NASDAQ: AFMD) announces FDA's RMAT designation for its combination therapy of acimtamig and AlloNK® for treating relapsed/refractory Hodgkin Lymphoma (R/R HL). The designation was granted based on impressive early efficacy data showing an 83.3% overall response rate and 50% complete response rate in 12 patients, with a well-managed safety profile.
The RMAT designation provides expedited review benefits similar to Breakthrough Therapy Designation, potentially accelerating the therapy's path to market. The combination therapy is currently being evaluated in the LuminICE-203 phase 2 trial, with complete data from all four cohorts to be presented at the 66th ASH Annual Meeting. The company also sees potential application in CD30 positive lymphomas, including peripheral T-cell lymphoma (PTCL).
Affimed N.V. (AFMD) reported Q3 2024 financial results and clinical updates. The company completed enrollment for its AFM24-atezolizumab combination NSCLC EGFRwt cohort, with data presentation scheduled for December 17, 2024. Cash position was €24.1 million as of September 30, 2024, with runway projected into Q4 2025. Q3 revenue decreased to €0.2 million from €2.0 million year-over-year. Net loss improved to €15.1 million (€0.94 per share) compared to €24.4 million (€1.63 per share) in Q3 2023. R&D expenses decreased to €10.1 million from €21.5 million, while G&A expenses reduced to €4.3 million from €5.4 million.
Affimed N.V. (Nasdaq: AFMD) announced it will release its third quarter 2024 financial results and corporate update on Thursday, November 14, 2024. The clinical-stage immuno-oncology company will host a conference call at 8:30 a.m. EST / 14:30 CET. Investors can access the live audio webcast through the company's website and participate in the call via phone by registering through the provided link. A replay will be available for 30 days following the call.
Affimed announced the acceptance of three abstracts for presentation at the 66th ASH Annual Meeting in December 2024. The presentations include clinical results from the AFM28 phase 1 dose escalation study in relapsed/refractory acute myeloid leukemia (AML), featuring promising efficacy and safety data. Additionally, preclinical data will showcase AFM28's in vitro efficacy combined with NK cells against leukemic blasts. The company will also present updated clinical results from the LuminICE-203 study evaluating acimtamig (AFM13) in combination with AlloNK® for relapsed/refractory Hodgkin Lymphoma.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced its participation in the Cantor Global Healthcare Conference 2024. CEO Shawn M. Leland will engage in a fireside chat on September 17, 2024, at 8:00 a.m. EDT / 14:00 CET.
A live webcast of the presentation will be available on Affimed's website, with a 30-day replay option. Investors interested in one-on-one meetings with Affimed's management can contact their Cantor Fitzgerald representative or reach out to Alex Fudukidis at a.fudukidis@affimed.com or +1 (917) 436-8102.
This event provides an opportunity for Affimed to showcase its progress in developing therapies that harness patients' innate ability to fight cancer.
Affimed N.V. (Nasdaq: AFMD) reported Q2 2024 financial results and provided clinical updates. Key highlights include:
1. AFM24 combination with atezolizumab: In EGFRmut NSCLC, 23.5% ORR and 70.6% DCR observed in 17 evaluable patients.
2. Acimtamig (AFM13) combination with AlloNK®: In r/r Hodgkin Lymphoma, 83.3% ORR and 50% CRR observed in 12 patients.
3. AFM28 monotherapy: In r/r AML, 50% CR/CRi rate observed in 6 patients at 300 mg dose.
4. Financial position: €34.4 million in cash and equivalents as of June 30, 2024, with runway into H2 2025.
5. Q2 2024 financials: €0.2 million revenue, €11.7 million R&D expenses, €4.0 million G&A expenses, and €15.5 million net loss.
Affimed N.V. (Nasdaq: AFMD) has appointed Shawn M. Leland as its new Chief Executive Officer. Leland brings over 15 years of experience in the pharmaceutical and biotechnology industry, with a strong track record in advancing oncology assets, raising capital, and establishing strategic partnerships. He previously served as Interim CEO of ForeBio and founded Elevation Oncology, where he raised over $200M in capital. Dr. Andreas Harstrick, who has been acting CEO since January 2024, will continue as Chief Medical Officer.
Leland's appointment comes as Affimed focuses on its three active clinical programs, with important data readouts expected in the near future. The company's strategy centers on harnessing the innate immune system to fight cancer, and Leland's expertise is expected to drive Affimed's growth and shape its corporate development strategy.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced that it will release its second quarter 2024 financial results and corporate update on September 5, 2024. The company will host a conference call at 8:30 a.m. EDT / 14:30 CET on the same day. Investors and interested parties can access the live audio webcast of the call through the 'Webcasts' section on Affimed's website. For those who prefer to join by phone, a registration link is provided to obtain dial-in details and a pin number. To ensure a timely start, participants are encouraged to dial in 15 minutes before the scheduled time. A replay of the webcast will be available for 30 days following the call.
Affimed reported its Q1 2024 financial results, revealing a significant decline in revenue to €0.2 million from €4.5 million in Q1 2023, due to decreased collaboration payments. However, operating expenses also decreased, with R&D expenses down to €15.4 million from €29.5 million and general administrative expenses down to €4.5 million from €6.9 million. Net loss improved to €19.2 million from €32 million in Q1 2023.
Clinical updates include promising results from the LuminICE-203 study, showing an 85.7% ORR in Hodgkin Lymphoma patients and 33% CR/CRi rate in the AFM28 monotherapy study. AFM24-a combination with atezolizumab in NSCLC patients showed a 71% disease control rate and a 5.9-month mPFS.
Financially, Affimed has a cash runway into H2 2025 with €48.5 million in cash and equivalents as of March 31, 2024.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
